Le Lézard
Classified in: Health

StatLab Medical Products Granted Patent for Tissue Microarray Controls


MCKINNEY, Texas, Sept. 21, 2019 /PRNewswire-PRWeb/ -- StatLab Medical Products is pleased to announce the receipt of patent No. 10,329,623, a novel method for development of an improved tissue-like control created by Dr. S. Ashraf Imam, Director of Advanced Diagnostics Research and Development at StatLab, and Dr. Mark Rees, SVP of Innovation and Research and Development at StatLab.

Dr. Mark Rees commented, "Standardization is critically important in pathology laboratories where improved monitoring of assay consistency can lead to more accurate diagnosis and prognosis for cancer patients. Until now, only patient archival tissue and cell lines have been available for use as controls for IHC, FISH, and CISH, but both have flaws with consistency and morphological appearance, respectively.

"Our research and development team, led by Dr. Ashraf Imam, identified the need for consistency, and developed the world's first true control technology that results in a product resembling the morphology of actual cancer tissue while providing true standardization. We're excited about the impact this will have in the industry."

"The granting of this patent reflects StatLab's commitment to providing access to quality products through focused research and development," said StatLab CEO, Dan Eckert. "We're building on our proven reputation of partnering with our customers to meet their needs."

The patented methods are used by TruQ Controlstm, launched by StatLab Medical Products. TruQ Controls are the industry's first 3D reference standard tissue controls that resemble human tissue and offer complete consistency. The product is in use by CIQC (Canadian Immunohistochemistry Quality Control) as part of their EQA (external quality assurance) testing protocols for laboratory proficiency, and in leading cancer centers. TruQ Controls have a wide range of potential applications, including monitoring of intra-assay variation, optimization and validation of antibodies, and interlaboratory standardization utilized in proficiency testing.

About StatLab Medical Products
Founded in 1976, StatLab Medical Products is ambitiously leading the way in development and manufacturing of high-quality histology, cytology and immunohistochemistry diagnostic products. We partner with anatomic pathology laboratories to provide easy access to over 3,500 high-quality diagnostic products and equipment at excellent prices, delivered with expert support. When you work with StatLab, we're on your team, and you're part of our family. Learn more at StatLab.com.

 

SOURCE StatLab


These press releases may also interest you

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...



News published on and distributed by: